1349875-71-3

Basic information

• Product Name: tert-butyl 6-acetyl-2,6-diazaspiro[3.3]heptane-2-carboxylate
• CAS NO: 1349875-71-3
• Molecular Weight: 240.302
• Mol File: 1349875-71-3.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 6-acetyl-2,6-diazaspiro[3.3]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-acetyl-2,6-diazaspiro[3.3]heptane-2-carboxylate(1349875-71-3)
• EPA Substance Registry System: tert-butyl 6-acetyl-2,6-diazaspiro[3.3]heptane-2-carboxylate(1349875-71-3)

Safety Data

• Hazardous Substances Data: 1349875-71-3(Hazardous Substances Data)

Upstream product

• 1041026-71-4 tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate salt 
• 75-36-5 acetyl chloride 
• 1041026-71-4 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester half oxalate 
• 1041026-70-3 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester hemioxylate 
• 108-24-7 acetic anhydride 

Downstream Products

• 1349875-74-6 1-(2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one hydrochloride 

Relevant articles and documents

SPIROCYCLIC ROR-GAMMA MODULATORS

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.